サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
デフォルト表紙
市場調査レポート
商品コード
1676162

炎症性腸疾患治療の世界市場調査レポート：産業分析、規模、シェア、成長、動向、2025年から2033年までの予測

Global Inflammatory Bowel Disease Treatment Market Research Report- Industry Analysis, Size, Share, Growth, Trends and Forecast 2025 to 2033

出版日
ページ情報
英文 143 Pages
納期
即日から翌営業日
カスタマイズ可能
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=144.06円
炎症性腸疾患治療の世界市場調査レポート：産業分析、規模、シェア、成長、動向、2025年から2033年までの予測
出版日: 2025年03月01日
発行: Value Market Research
ページ情報: 英文 143 Pages
納期: 即日から翌営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 図表
  • 目次
概要

炎症性腸疾患治療の世界市場規模は、2024年の266億6,000万米ドルから2033年には463億2,000万米ドルに成長し、2026～2033年の予測期間中に6.33%の堅調な年間平均成長率（CAGR）を示すと予測されます。

炎症性腸疾患（IBD）治療市場は、クローン病や潰瘍性大腸炎を含むIBDの有病率が世界的に上昇し続けていることから、大きな成長を遂げています。IBDは消化管の炎症を特徴とする慢性疾患で、腹痛、下痢、倦怠感などの症状を引き起こします。IBDに対する意識の高まりと生活の質への影響は、効果的な治療オプションに対する需要を促進しています。医療プロバイダーが患者の予後を改善し、症状をより効果的に管理しようと努める中、IBD治療市場は繁栄が見込まれています。

技術の進歩はIBD治療市場の将来を形成する上で重要な役割を果たしています。モノクローナル抗体や低分子を含む生物学的治療法の革新は、炎症を抑え寛解を誘導することを目的とした治療の有効性を高めています。さらに、薬理ゲノミクスのような個別化医療の進歩により、医療プロバイダーは個々の患者プロファイルに基づいて治療をカスタマイズできるようになり、治療成績が向上しています。製薬企業が研究開発への投資を続けていることから、IBD治療市場は新規治療法の採用や管理戦略の改善が進むとみられます。

さらに、全人的ケアと患者サポートを重視する傾向が強まっていることも、IBD治療市場の成長軌道に影響を与えています。患者が治療のペイシェントジャーニーに参加するようになるにつれ、医療的要因とライフスタイル要因の両方に対処する包括的なケアプランに対する需要が高まっています。この動向は、医療プロバイダー、栄養士、患者支援団体が協力し、患者の病状管理に力を与える教育リソースや支援ネットワークを開発する原動力となっています。市場が進化を続ける中、技術、患者参加、ホリスティックなアプローチの統合が成功の重要な要因となると考えられます。

当社のレポートは、様々な産業や市場に関する包括的かつ実用的な洞察をクライアントに提供するために綿密に作成されています。各レポートは、市場情勢を完全に理解するために、いくつかの重要な要素を含んでいます。

市場概要：市場概要：定義、分類、産業の現状など、市場に関する詳細なイントロダクション。

市場促進要因：市場成長に影響を与える主要促進要因・抑制要因・市場促進要因・課題を詳細に分析します。このセクションでは、技術の進歩、規制の変更、新たな動向などの要因を検証します。

セグメンテーション分析：製品タイプ、用途、エンドユーザー、地域などの基準に基づき、市場を明確なセグメントに内訳。この分析により、各セグメントの業績と将来性を明らかにします。

競合情勢：市場シェア、製品ポートフォリオ、戦略的イニシアティブ、財務実績など、主要市場参入企業の包括的評価。主要企業が採用する競合力学と主要戦略に関する考察を記載しています。

市場予測：過去のデータと現在の市場状況に基づき、一定期間における市場規模と成長動向を予測。これには、定量的分析と将来の市場軌跡を示すグラフ表示が含まれます。

地域分析：地域による市場パフォーマンスを評価し、主要市場や地域動向を明らかにします。地域の市場力学とビジネス機会を理解するのに役立ちます。

新たな動向と機会：現在の市場動向と新たな市場動向、技術革新、潜在的な投資対象セグメントを特定します。将来の市場開拓と成長展望に関する洞察を記載しています。

目次

第1章 序文

第2章 エグゼクティブサマリー

  • 市場のハイライト
  • 世界市場スナップショット

第3章 炎症性腸疾患治療：産業分析

  • イントロダクション-市場力学
  • 市場促進要因
  • 市場抑制要因
  • 機会
  • 産業動向
  • ポーターのファイブフォース分析
  • 市場の魅力分析

第4章 バリューチェーン分析

  • バリューチェーン分析
  • 原料分析
    • 原料リスト
    • 原料メーカー一覧
    • 主要原料の価格動向
  • 潜在的バイヤーリスト
  • マーケティングチャネル
    • 直接マーケティング
    • 間接マーケティング
    • マーケティングチャネル発展動向

第5章 炎症性腸疾患治療の世界市場分析：薬剤タイプ別

  • 薬剤タイプ別概要
  • 薬剤タイプ別過去・予測データ分析
  • アミノサリチル酸塩
  • 副腎皮質ステロイド薬
  • 免疫調節薬
  • 生物製剤
  • その他

第6章 炎症性腸疾患治療の世界市場分析：疾患タイプ別

  • 疾患タイプ別概要
  • 疾患タイプ別過去・予測データ分析
  • 潰瘍性大腸炎
  • クローン病

第7章 炎症性腸疾患治療の世界市場分析：流通チャネル別

  • 流通チャネル別概要
  • 流通チャネル別過去・予測データ分析
  • 病院薬局
  • 小売薬局
  • オンライン薬局

第8章 炎症性腸疾患治療の世界市場分析：投与経路別

  • 投与経路別概要
  • 投与経路別過去・予測データ分析
  • 経口剤
  • 注射剤

第9章 炎症性腸疾患治療の世界市場分析：地域別

  • 地域別展望
  • イントロダクション
  • 北米売上分析
    • 概要、実績と予測
    • 北米：セグメント別
    • 北米：国別
    • 米国
    • カナダ
    • メキシコ
  • 欧州売上分析
    • 概要、実績と予測
    • 欧州：セグメント別
    • 欧州：国別
    • 英国
    • フランス
    • ドイツ
    • イタリア
    • ロシア
    • その他の欧州
  • アジア太平洋売上分析
    • 概要、実績と予測
    • アジア太平洋：セグメント別
    • アジア太平洋：国別
    • 中国
    • インド
    • 日本
    • 韓国
    • オーストラリア
    • 東南アジア
    • その他のアジア太平洋
  • ラテンアメリカ売上分析
    • 概要、実績と予測
    • ラテンアメリカ：セグメント別
    • ラテンアメリカ：国別
    • ブラジル
    • アルゼンチン
    • ペルー
    • チリ
    • その他のラテンアメリカ
  • 中東・アフリカ売上分析
    • 概要、実績と予測
    • 中東・アフリカ：セグメント別
    • 中東・アフリカ：国別一覧
    • サウジアラビア
    • アラブ首長国連邦
    • イスラエル
    • 南アフリカ
    • その他の中東・アフリカ

第10章 炎症性腸疾患治療企業の競合情勢

  • 炎症性腸疾患治療市場競争
  • 提携・協力・契約
  • 合併・買収
  • 新製品の上市
  • その他の開発

第11章 企業プロファイル

  • 上位企業の市場シェア分析
  • 市場集中度
  • AbbVie Inc.
  • Johnson & Johnson
  • Takeda Pharmaceutical Company Limited
  • Pfizer Inc.
  • Roche Holding AG
  • Novartis AG
  • Eli Lilly And Company
  • Merck & Co. Inc.
  • Sanofi S.A.
  • Amgen Inc.
  • UCB S.A.
  • Biogen Inc.
  • GlaxoSmithKline Plc
  • Bristol-Myers Squibb Company
  • AstraZeneca PLC
図表

LIST OF TABLES

  • Market Snapshot
  • Drivers: Impact Analysis
  • Restraints: Impact Analysis
  • List of Raw Material
  • List of Raw Material Manufactures
  • Analysis By Drug Type (USD MN)
  • Aminosalicylates Market Sales By Geography (USD MN)
  • Corticosteroids Market Sales By Geography (USD MN)
  • Immunomodulators Market Sales By Geography (USD MN)
  • Biologics Market Sales By Geography (USD MN)
  • Others Market Sales By Geography (USD MN)
  • Analysis By Disease Type (USD MN)
  • Ulcerative Colitis Market Sales By Geography (USD MN)
  • Crohn's Disease Market Sales By Geography (USD MN)
  • Analysis By Distribution Channel (USD MN)
  • Hospital Pharmacies Market Sales By Geography (USD MN)
  • Retail Pharmacies Market Sales By Geography (USD MN)
  • Online Pharmacies Market Sales By Geography (USD MN)
  • Analysis By Route of Administration (USD MN)
  • Oral Market Sales By Geography (USD MN)
  • Injectable Market Sales By Geography (USD MN)
  • Global Inflammatory Bowel Disease Treatment Market Sales By Geography (USD MN)
  • North America Market Analysis (USD MN)
  • United States Market Analysis (USD MN)
  • Canada Market Analysis (USD MN)
  • Mexico Market Analysis (USD MN)
  • Europe Market Analysis (USD MN)
  • Europe Market Estimate By Country (USD MN)
  • United Kingdom Market Analysis (USD MN)
  • France Market Analysis (USD MN)
  • Germany Market Analysis (USD MN)
  • Italy Market Analysis (USD MN)
  • Russia Market Analysis (USD MN)
  • Spain Market Analysis (USD MN)
  • Rest of Europe Market Analysis (USD MN)
  • Asia Pacific Market Analysis (USD MN)
  • China Market Analysis (USD MN)
  • Japan Market Analysis (USD MN)
  • India Market Analysis (USD MN)
  • South Korea Market Analysis (USD MN)
  • Australia Market Analysis (USD MN)
  • South East Asia Market Analysis (USD MN)
  • Rest of Asia Pacific Market Analysis (USD MN)
  • Latin America Market Analysis (USD MN)
  • Brazil Market Analysis (USD MN)
  • Argentina Market Analysis (USD MN)
  • Peru Market Analysis (USD MN)
  • Chile Market Analysis (USD MN)
  • Rest of Latin America Market Analysis (USD MN)
  • Middle East & Africa Market Analysis (USD MN)
  • Saudi Arabia Market Analysis (USD MN)
  • UAE Market Analysis (USD MN)
  • Israel Market Analysis (USD MN)
  • South Africa Market Analysis (USD MN)
  • Rest of Middle East and Africa Market Analysis (USD MN)
  • Partnership/Collaboration/Agreement
  • Mergers And Acquisition

LIST OF FIGURES

  • Research Scope of Inflammatory Bowel Disease Treatment Report
  • Market Research Process
  • Market Research Methodology
  • Global Inflammatory Bowel Disease Treatment Market Size, By Region (USD MN)
  • Porters Five Forces Analysis
  • Market Attractiveness Analysis By Drug Type
  • Market Attractiveness Analysis By Disease Type
  • Market Attractiveness Analysis By Distribution Channel
  • Market Attractiveness Analysis By Route of Administration
  • Market Attractiveness Analysis By Region
  • Value Chain Analysis
  • Global Market Analysis By Drug Type (USD MN)
  • Aminosalicylates Market Sales By Geography (USD MN)
  • Corticosteroids Market Sales By Geography (USD MN)
  • Immunomodulators Market Sales By Geography (USD MN)
  • Biologics Market Sales By Geography (USD MN)
  • Others Market Sales By Geography (USD MN)
  • Global Market Analysis By Disease Type (USD MN)
  • Ulcerative Colitis Market Sales By Geography (USD MN)
  • Crohn's Disease Market Sales By Geography (USD MN)
  • Global Market Analysis By Distribution Channel (USD MN)
  • Hospital Pharmacies Market Sales By Geography (USD MN)
  • Retail Pharmacies Market Sales By Geography (USD MN)
  • Online Pharmacies Market Sales By Geography (USD MN)
  • Global Market Analysis By Route of Administration (USD MN)
  • Oral Market Sales By Geography (USD MN)
  • Injectable Market Sales By Geography (USD MN)
  • Global Market Sales (USD MN)
  • North America Market Sales (USD MN)
  • Europe Market Sales (USD MN)
  • Asia Pacific Market Sales (USD MN)
  • Latin America Market Sales (USD MN)
  • Middle East & Africa Market Sales (USD MN)
  • Recent Development in Industry
  • Top Company Market Share Analysis

Kindly note that the above listed are the basic tables and figures of the report and are not limited to the TOC.

目次
Product Code: VMR11219393

Global Inflammatory Bowel Disease Treatment Market size is anticipated to grow from USD 26.66 Billion in 2024 to USD 46.32 Billion by 2033, showcasing a robust Compound Annual Growth Rate (CAGR) of 6.33% during the forecast period of 2026 to 2033.

The Inflammatory Bowel Disease (IBD) Treatment Market is experiencing significant growth as the prevalence of IBD, including Crohn's disease and ulcerative colitis, continues to rise globally. IBD is a chronic condition characterized by inflammation of the gastrointestinal tract, leading to symptoms such as abdominal pain, diarrhea, and fatigue. The increasing awareness of IBD and its impact on quality of life is driving the demand for effective treatment options. As healthcare providers seek to improve patient outcomes and manage symptoms more effectively, the market for IBD treatments is expected to flourish.

Technological advancements are playing a crucial role in shaping the future of the IBD treatment market. Innovations in biologic therapies, including monoclonal antibodies and small molecules, are enhancing the efficacy of treatments aimed at reducing inflammation and inducing remission. Additionally, advancements in personalized medicine, such as pharmacogenomics, are enabling healthcare providers to tailor treatments based on individual patient profiles, improving therapeutic outcomes. As pharmaceutical companies continue to invest in research and development, the IBD treatment market is likely to see increased adoption of novel therapies and improved management strategies.

Moreover, the growing emphasis on holistic care and patient support is influencing the IBD treatment market's growth trajectory. As patients become more engaged in their treatment journeys, there is a rising demand for comprehensive care plans that address both medical and lifestyle factors. This trend is driving collaboration between healthcare providers, nutritionists, and patient advocacy groups to develop educational resources and support networks that empower patients in managing their condition. As the market continues to evolve, the integration of technology, patient engagement, and holistic approaches will be key drivers of success.

Our reports are meticulously crafted to provide clients with comprehensive and actionable insights into various industries and markets. Each report encompasses several critical components to ensure a thorough understanding of the market landscape:

Market Overview: A detailed introduction to the market, including definitions, classifications, and an overview of the industry's current state.

Market Dynamics: In-depth analysis of key drivers, restraints, opportunities, and challenges influencing market growth. This section examines factors such as technological advancements, regulatory changes, and emerging trends.

Segmentation Analysis: Breakdown of the market into distinct segments based on criteria like product type, application, end-user, and geography. This analysis highlights the performance and potential of each segment.

Competitive Landscape: Comprehensive assessment of major market players, including their market share, product portfolio, strategic initiatives, and financial performance. This section provides insights into the competitive dynamics and key strategies adopted by leading companies.

Market Forecast: Projections of market size and growth trends over a specified period, based on historical data and current market conditions. This includes quantitative analyses and graphical representations to illustrate future market trajectories.

Regional Analysis: Evaluation of market performance across different geographical regions, identifying key markets and regional trends. This helps in understanding regional market dynamics and opportunities.

Emerging Trends and Opportunities: Identification of current and emerging market trends, technological innovations, and potential areas for investment. This section offers insights into future market developments and growth prospects.

SEGMENTATION COVERED IN THE REPORT

By Drug Type

  • Aminosalicylates
  • Corticosteroids
  • Immunomodulators
  • Biologics
  • Others

By Disease Type

  • Ulcerative Colitis
  • Crohn's Disease

By Distribution Channel

  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies

By Route of Administration

  • Oral
  • Injectable
  • COMPANIES PROFILED
  • AbbVie Inc.
  • Johnson & Johnson
  • Takeda Pharmaceutical Company Limited
  • Pfizer Inc.
  • Roche Holding AG
  • Novartis AG
  • Eli Lilly and Company
  • Merck & Co. Inc.
  • Sanofi S.A.
  • Amgen Inc.
  • UCB S.A.
  • Biogen Inc.
  • GlaxoSmithKline plc
  • Bristol-Myers Squibb Company
  • AstraZeneca PLC
  • The above list can be customized.

TABLE OF CONTENTS

1. PREFACE

  • 1.1. Report Description
    • 1.1.1 Objective
    • 1.1.2 Target Audience
    • 1.1.3 Unique Selling Proposition (USP) & offerings
  • 1.2. Research Scope
  • 1.3. Research Methodology
    • 1.3.1 Market Research Process
    • 1.3.2 Market Research Methodology

2. EXECUTIVE SUMMARY

  • 2.1. Highlights of Market
  • 2.2. Global Market Snapshot

3. INFLAMMATORY BOWEL DISEASE TREATMENT a€" INDUSTRY ANALYSIS

  • 3.1. Introduction - Market Dynamics
  • 3.2. Market Drivers
  • 3.3. Market Restraints
  • 3.4. Opportunities
  • 3.5. Industry Trends
  • 3.6. Porters Five Force Analysis
  • 3.7. Market Attractiveness Analysis
    • 3.7.1 Market Attractiveness Analysis By Drug Type
    • 3.7.2 Market Attractiveness Analysis By Disease Type
    • 3.7.3 Market Attractiveness Analysis By Distribution Channel
    • 3.7.4 Market Attractiveness Analysis By Route of Administration
    • 3.7.5 Market Attractiveness Analysis By Region

4. VALUE CHAIN ANALYSIS

  • 4.1. Value Chain Analysis
  • 4.2. Raw Material Analysis
    • 4.2.1 List of Raw Materials
    • 4.2.2 Raw Material Manufactures List
    • 4.2.3 Price Trend of Key Raw Materials
  • 4.3. List of Potential Buyers
  • 4.4. Marketing Channel
    • 4.4.1 Direct Marketing
    • 4.4.2 Indirect Marketing
    • 4.4.3 Marketing Channel Development Trend

5. GLOBAL INFLAMMATORY BOWEL DISEASE TREATMENT MARKET ANALYSIS BY DRUG TYPE

  • 5.1. Overview By Drug Type
  • 5.2. Historical and Forecast Data Analysis By Drug Type
  • 5.3. Aminosalicylates Historic and Forecast Sales By Regions
  • 5.4. Corticosteroids Historic and Forecast Sales By Regions
  • 5.5. Immunomodulators Historic and Forecast Sales By Regions
  • 5.6. Biologics Historic and Forecast Sales By Regions
  • 5.7. Others Historic and Forecast Sales By Regions

6. GLOBAL INFLAMMATORY BOWEL DISEASE TREATMENT MARKET ANALYSIS BY DISEASE TYPE

  • 6.1. Overview By Disease Type
  • 6.2. Historical and Forecast Data Analysis By Disease Type
  • 6.3. Ulcerative Colitis Historic and Forecast Sales By Regions
  • 6.4. Crohn's Disease Historic and Forecast Sales By Regions

7. GLOBAL INFLAMMATORY BOWEL DISEASE TREATMENT MARKET ANALYSIS BY DISTRIBUTION CHANNEL

  • 7.1. Overview By Distribution Channel
  • 7.2. Historical and Forecast Data Analysis By Distribution Channel
  • 7.3. Hospital Pharmacies Historic and Forecast Sales By Regions
  • 7.4. Retail Pharmacies Historic and Forecast Sales By Regions
  • 7.5. Online Pharmacies Historic and Forecast Sales By Regions

8. GLOBAL INFLAMMATORY BOWEL DISEASE TREATMENT MARKET ANALYSIS BY ROUTE OF ADMINISTRATION

  • 8.1. Overview By Route of Administration
  • 8.2. Historical and Forecast Data Analysis By Route of Administration
  • 8.3. Oral Historic and Forecast Sales By Regions
  • 8.4. Injectable Historic and Forecast Sales By Regions

9. GLOBAL INFLAMMATORY BOWEL DISEASE TREATMENT MARKET ANALYSIS BY GEOGRAPHY

  • 9.1. Regional Outlook
  • 9.2. Introduction
  • 9.3. North America Sales Analysis
    • 9.3.1 Overview, Historic and Forecast Data Sales Analysis
    • 9.3.2 North America By Segment Sales Analysis
    • 9.3.3 North America By Country Sales Analysis
    • 9.3.4 United States Sales Analysis
    • 9.3.5 Canada Sales Analysis
    • 9.3.6 Mexico Sales Analysis
  • 9.4. Europe Sales Analysis
    • 9.4.1 Overview, Historic and Forecast Data Sales Analysis
    • 9.4.2 Europe By Segment Sales Analysis
    • 9.4.3 Europe By Country Sales Analysis
    • 9.4.4 United Kingdom Sales Analysis
    • 9.4.5 France Sales Analysis
    • 9.4.6 Germany Sales Analysis
    • 9.4.7 Italy Sales Analysis
    • 9.4.8 Russia Sales Analysis
    • 9.4.9 Rest Of Europe Sales Analysis
  • 9.5. Asia Pacific Sales Analysis
    • 9.5.1 Overview, Historic and Forecast Data Sales Analysis
    • 9.5.2 Asia Pacific By Segment Sales Analysis
    • 9.5.3 Asia Pacific By Country Sales Analysis
    • 9.5.4 China Sales Analysis
    • 9.5.5 India Sales Analysis
    • 9.5.6 Japan Sales Analysis
    • 9.5.7 South Korea Sales Analysis
    • 9.5.8 Australia Sales Analysis
    • 9.5.9 South East Asia Sales Analysis
    • 9.5.10 Rest Of Asia Pacific Sales Analysis
  • 9.6. Latin America Sales Analysis
    • 9.6.1 Overview, Historic and Forecast Data Sales Analysis
    • 9.6.2 Latin America By Segment Sales Analysis
    • 9.6.3 Latin America By Country Sales Analysis
    • 9.6.4 Brazil Sales Analysis
    • 9.6.5 Argentina Sales Analysis
    • 9.6.6 Peru Sales Analysis
    • 9.6.7 Chile Sales Analysis
    • 9.6.8 Rest of Latin America Sales Analysis
  • 9.7. Middle East & Africa Sales Analysis
    • 9.7.1 Overview, Historic and Forecast Data Sales Analysis
    • 9.7.2 Middle East & Africa By Segment Sales Analysis
    • 9.7.3 Middle East & Africa By Country Sales Analysis
    • 9.7.4 Saudi Arabia Sales Analysis
    • 9.7.5 UAE Sales Analysis
    • 9.7.6 Israel Sales Analysis
    • 9.7.7 South Africa Sales Analysis
    • 9.7.8 Rest Of Middle East And Africa Sales Analysis

10. COMPETITIVE LANDSCAPE OF THE INFLAMMATORY BOWEL DISEASE TREATMENT COMPANIES

  • 10.1. Inflammatory Bowel Disease Treatment Market Competition
  • 10.2. Partnership/Collaboration/Agreement
  • 10.3. Merger And Acquisitions
  • 10.4. New Product Launch
  • 10.5. Other Developments

11. COMPANY PROFILES OF INFLAMMATORY BOWEL DISEASE TREATMENT INDUSTRY

  • 11.1. Top Companies Market Share Analysis
  • 11.2. Market Concentration Rate
  • 11.3. AbbVie Inc.
    • 11.3.1 Company Overview
    • 11.3.2 Company Revenue
    • 11.3.3 Products
    • 11.3.4 Recent Developments
  • 11.4. Johnson & Johnson
    • 11.4.1 Company Overview
    • 11.4.2 Company Revenue
    • 11.4.3 Products
    • 11.4.4 Recent Developments
  • 11.5. Takeda Pharmaceutical Company Limited
    • 11.5.1 Company Overview
    • 11.5.2 Company Revenue
    • 11.5.3 Products
    • 11.5.4 Recent Developments
  • 11.6. Pfizer Inc.
    • 11.6.1 Company Overview
    • 11.6.2 Company Revenue
    • 11.6.3 Products
    • 11.6.4 Recent Developments
  • 11.7. Roche Holding AG
    • 11.7.1 Company Overview
    • 11.7.2 Company Revenue
    • 11.7.3 Products
    • 11.7.4 Recent Developments
  • 11.8. Novartis AG
    • 11.8.1 Company Overview
    • 11.8.2 Company Revenue
    • 11.8.3 Products
    • 11.8.4 Recent Developments
  • 11.9. Eli Lilly And Company
    • 11.9.1 Company Overview
    • 11.9.2 Company Revenue
    • 11.9.3 Products
    • 11.9.4 Recent Developments
  • 11.10. Merck & Co. Inc.
    • 11.10.1 Company Overview
    • 11.10.2 Company Revenue
    • 11.10.3 Products
    • 11.10.4 Recent Developments
  • 11.11. Sanofi S.A.
    • 11.11.1 Company Overview
    • 11.11.2 Company Revenue
    • 11.11.3 Products
    • 11.11.4 Recent Developments
  • 11.12. Amgen Inc.
    • 11.12.1 Company Overview
    • 11.12.2 Company Revenue
    • 11.12.3 Products
    • 11.12.4 Recent Developments
  • 11.13. UCB S.A.
    • 11.13.1 Company Overview
    • 11.13.2 Company Revenue
    • 11.13.3 Products
    • 11.13.4 Recent Developments
  • 11.14. Biogen Inc.
    • 11.14.1 Company Overview
    • 11.14.2 Company Revenue
    • 11.14.3 Products
    • 11.14.4 Recent Developments
  • 11.15. GlaxoSmithKline Plc
    • 11.15.1 Company Overview
    • 11.15.2 Company Revenue
    • 11.15.3 Products
    • 11.15.4 Recent Developments
  • 11.16. Bristol-Myers Squibb Company
    • 11.16.1 Company Overview
    • 11.16.2 Company Revenue
    • 11.16.3 Products
    • 11.16.4 Recent Developments
  • 11.17. AstraZeneca PLC
    • 11.17.1 Company Overview
    • 11.17.2 Company Revenue
    • 11.17.3 Products
    • 11.17.4 Recent Developments

Note - In company profiling, financial details and recent developments are subject to availability or might not be covered in the case of private companies